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Using genetically engineered endogenous lactobacillus strains colonizing the vagina mucosa to 
express heterogenous proteins has of late joined the novel strategies aimed at developing a 
microbicides against HIV. Using the lactobacillus metabolic genome pathway, we found that these 
bacteria do not naturally produce restriction enzymes, but rather, have a number of putative alien genes 
of the type. In view of the antiviral defence role of restriction modification systems (RMS), we searched 
for enzymes that cleave HIV-1, 2 and other SIV genomes using theoretical computational methods. With 
over 200 such enzymes identified, we present herein a plasmid vector mediated strategy for modifying 
lactobacillus strains to express RMS islands as an approach to developing a live HIV microbicide. This 
model is transferable to other viral infections that find their way into humans through mucosal orifices.  
 






In the wake of increased virologic failure, resistance and 
toxicity to the currently approved Highly Active Antiretro-
viral Therapy (HAART) combinations (Mansky et al., 
1995; DHHS, 2006; Hammer et al., 2006; Bartlett et al., 
2006; Bartlett et al., 2001; Mayer et al., 2006), newer HIV 
inhibitory products are being explored (Gulick et al., 
2006; Sansone et al., 2006; Pugach et al., 2006; Anasta-
sopoulou et al., 2006; Norris et al., 2005; Norris et al., 
2006; Davison et al., 2006; Delmedico et al., 2006; 
Markowitz et al., 2006). Many gene based models are 
currently being researched, ranging from the use of 
U1snRNAs to inhibit gene expression, RNA interference 
pathway to stop early and late HIV replication through 
post transcriptional gene slicing, and autologous T cell 
anti-HIV anti-sense Ribonucleic acid (RNA) delivered by 
the VRX496 lentiviral vector to ribozyme enzymes 
cleaving HIV RNA (Sajic et al., 2006; Barichievy et al., 
2006; Meshcheryakova et al., 2006; Trebello et a., 2006; 
Liu et al., 2006). Recently, the use of recombinant lacto-
bacillus developed by genetically modifying native vagi-
nocervical (VC) commensal strains for use as live 
microbicides has became plausible strategy for pre-
venting sexual transmission of HIV in women. 
Base on the natural bacteria “restriction modification 
system (RMS) immune model (Murray, 2000; Nelson, 
1972; Roberts and Macelis, 1991; Janulaitis et al 1992; 
Kessler and Manta, 1990; Nelson and McClelland, 1991; 
Radasci and Bickle, 1996; Barcus and Murray, 1995; 
Misaki, 2005) that renders bacteria cells immune to viral 
tropism through the production of restriction enzymes that 
recognize 4-8 bps nucleotide sequences in the invading 
DNA and cleave it, we hypothesized that, by modifying 
human cells susceptible to HIV tropism to accord the 
RMS properties, we could develop human gene therapies 
against HIV. Prospective in vivo viral-vector mediated 
delivery strategies for modifying human cells susceptible 
to HIV in this way were, however, overshadowed by the 
foresight of immunologic rejection and unpredictable 
safety (Web cutter Version 2.0. http://rna.lund-
berg.gu.se/cutter2/; Perelson et al., 1996; Perelson et al., 
1997; Miller et al., 1993; Jolly, 1994; Weissman et al., 





very;  say  by genetically modifying a native VC lactobaci-
llus strain to accord it restriction and modification proper-
ties of RMS with potent activity against HIV genomes, if 
any, we could develop a novel live microbicide against 
HIV (Coombs et al., 2003; Bardeguez et al., 1997; Givan 
et al., 1997). We set of to analyse the pre-existing lacto-
bacillus restriction and modification abilities, and search 
for other bacteria restriction enzymes that can cleave HIV 
1, 2 and SIV genomes for use in this quest, and present 







Computer simulated assays, lactobacillus pathway genome data 
base [PGDB] search, and recombinant plasmid-vector-mediated 





291 restriction enzymes from Promega database (http://www.pro-
mega.com/default.asp), the curated metabolic pathway genome of 
Lactobacillus plantinuum-LacplantCyc (http://www.lacplantcyc.nl/): 
the 9037 base pair HIV-1/SIVcpz (A1.BY.97.97BL006_AF193275), 
9713 base pair HIV-2/SIVssm (A.GM.x.MCN13_AY509259) and 
9719 base pair other SIV (B.FR.83.HXB2_LAI_IIIB_BRU_K03455) 
genomes obtained from the HIV gene sequence database 
(www.hiv.lanl.gov/content/hiv-db/ALIGN_CURRENT/ALIGN-
INDEX.html, webcutter version2 (http://rna.lundberg.gu.se/cutter2/), 
pOSEL144 (Web cutter Version 2.0. http://rna.lundberg.gu.se/cut-






We searched for restriction enzymes cleaving the HIV genomes by 
feeding the above HIV subtype 1, 2 and other SIV whole genome in 
webcutter version 2.0 preset to recognize 6 palindromic nucleoside 
base pair sequences. In addition, we prompted the LacplantCyc 
pathway of L. plantinuum to identify lactobacilli restriction enzyme 
producing abilities. The biotechnology strategies for modifying the 
plasmid pOSEL144 to express heterogenous protens was reviewed 
on PubMED using a search dated 17/03/2007 prompted by the key 





Webcutter V2.0 preset to identify enzymes  
 
Of the 291 enzymes analyzed, 222 (76.3%) cleaved the 
HIV-1/SIVcpz genome as compared to 201 (69.1%) and 
207 (71.1%) for HIV-2/SIVssm and other SIV respective-
ly. 17 (5.8%) enzymes had 10 or > cuts in the HIV-
1/SIVcpz genome as compared to 25 (8.9%) and 18 
(6.2%) for HIV-2/SIVssm and other SIV, respectively. 
There were 6 of the enzymes demonstrating a mutual 
potent activity of 10 or > cuts against all three HIV-1/HIV- 
2/SIV genomes: Eco-130, EcoT141, ApoI, AcsI, BssTII, 
and StyI (Tables 1 - 4). 




LacplantCyc pathway genome database  
 
Of the 129 pathways and 704 predicted reactions invol-
ving some 670 chemical species and 710 enzymes, none 
originally involved the production of a restriction enzyme 
by lactobacillus. However, among putative alien genes 
acquired by horizontal gene transfer, there was one RMS 
genotype within the Lactobacillus PGDB, of Staphylococ-
cus aureus origin: hsdR (putative type I restriction enzy-
me) and hsdM protein (methyltranferase). This implies 
that the native strains of lactobacillus do not naturally 
produce restriction enzymes (Coombs et al., 2003; Bard-
eguez et al., 1997; Givan et al., 1997; Patterson et al., 
1998; Hladik et al., 1999; Anderson et al., 1998; Belec et 
al., 1995; Canchaya et al., 2006; Clerici, 1999; McLean 
and Rosenstein, 2000; Klebanoff, 1991; Theresa et al., 
2003; Liu., et al 2006) (Table 5) 
 
 
Plasmid vector pOSEL144 
 
Searching PubMED, 22755 papers were found on plas-
mid vector pOSEL144. A summary of the latest literature 
revealed that plasmid vector pOSEL144 is readily amen-
able to modifications for use in engineering strains of 
lactobacilli expressing heterogeneous proteins. Chang et 
al. (2003) recently demonstrated inhibition of HIV infec-
tivity by a natural human isolate of Lactobacillus jensenii 
engineered to express functional two-domain CD4 using 
a similar technology (Theresa et al., 2003). More recent-
ly, Liu et al. (2006) demonstrated Engineered Vaginal 
Lactobacillus Strain for Mucosal Delivery of the Human 
Immunodeficiency Virus Inhibitor Cyanovirin-N (Liu et al., 
2006). Using pOSEL144 modified to carry restriction enz-
ymes cleaving the HIV genome, it is therefore possible to 






Our results indicate that the HIV genome is still highly 
susceptible to the activity of various restriction enzymes, 
and many enzymes have the ability to cleave the genome 
in more than one place, with 17 (5.8%), 25 (8.9%) and 18 
(6.2%) cleaving HIV-1/SIVcpz, HIV-2/SIVssm and Other 
SIV in 10. or more areas respectively. The size of geno-
me has no influence on enzyme activity, but rather the 
presence of specificity palindromes. Taking the smaller 
HIV-1/SIVcpz genome A1.BY.97.97BL006_AF-193275 
with 9037 base pairs for instance, we observed that 222 
(76.3%) cleaved this gene compared to 201 (69.1) for the 
HIV-2/SIVssm A.GM.x.MCN13_AY509259 genome with 
9713 base pairs and 207 (71.1) in the Other SIV genome 
B.FR.83.HXB2_LAI_IIIB_BRU_K03455 with 9719 base 
pairs.  
Generally, there are four classes of restriction modifica-
tion systems (RMS), with each class possessing differing 
biochemical structure and function. Within the same class 
of RMS however, genes from one bacteria species are




Table 1. Summary of Enzyme activity cutting 10 or > times. 
 
Summary of Enzyme activity cutting 10 or > times 
Of the 291 enzymes analyzed, 222 (76.3%) cleaved the HIV-1/SIVcpz genome as compared to 201 (69.1%) and 
207 (71.1%) for HIV-2/SIVssm and Other SIV respectively. 17(5.8%) enzymes exhibited 10 or > cuts [x 10=2 
(BseRI, DraI), x 11=3 (BanII, Eco24I ,FriOI), x 13=3 (Eam1104I, EarI, Ksp632I), x 16=5 (BssT1I, Eco130I, 
EcoT14I, ErhI, StyI), x 17=2 (BstSFI, SfcI), and x 24=2 (AcsI, ApoI)] in the HIV-1/SIVcpz genome as compared 
to 25(8.9%) for HIV-2/SIVssm[x10=9(AccB1I, BanI, BshNI, DraII ,Eam1104I, EarI, Eco64I, EcoO109I, Ksp632I), 
x11=9 (BssT1I, BstSFI, CfrI, EaeI, Eco130I, EcoT14I, ErhI,SfcI, StyI), x 12=5 (BstYI, MflI, MspA1I, NspBII, 
XhoII), x16=2 (AcsI, ApoI) and 18 (6.2%).  For Other SIV [x10=3(MslI, MspA1I, NspBII), x11=2 (DraI, Eco57I), 
x12=5 (BssT1I, Eco130I, EcoT14I, ErhI, StyI), x13=2 (BstSFI, SfcI), x17=6 (AcsI, ApoI, BstX2I, BstYI, MflI, 
XhoII). Details of enzyme activity on each HIV genomes are shown in Tables 1, 2 and 3. 
HIV subtype/(genome)/bps/N(%) enzymes No. cuts Enzymes: Number (Name) 
10 2 (BseRI, DraI), 
11 3 (BanII, Eco24I, FriOI) 
13 3 (Eam1104I, EarI, Ksp632I) 
16 5 (BssT1I, Eco130I, EcoT14I, ErhI, StyI) 




/9037 base pairs/17(5.8%) 
 
 24 2 (AcsI, ApoI) 
10 9 (AccB1I, BanI, BshNI, DraII, Eam1104I, EarI, 
Eco64I, EcoO109I, Ksp632I) 
11 9 (BssT1I, BstSFI, CfrI, EaeI, Eco130I, EcoT14I, 
ErhI, SfcI, StyI) 
12 5 BstYI, MflI, MspA1I, NspBII, XhoII) 
HIV-2/SIVssm/ (A.GM.x.MCN13_AY509259)/ 








Table 2. Putative enzyme activity on HIV-1/SIVcpz genome A1.BY.97.97BL006_ AF193275 (9037 
base pairs). 
 
Frequency of cuts No. of enzyme (%) Enzymes cleaving 10 or > times  
1 72 (24.7) 
2 46 (15.8) 
3 16 (5.5) 
4 13 (4.5) 
5 20 (6.9) 
6 19 (6.5) 
7 14 (4.8) 
8 4 (1.4) 
9 1 (0.0) 
10 2 (0.7) 
11 3 (1.0) 
13 3 (1.0) 
16 5 (1.7) 
17 2 (0.7) 




x 10 (BseRI, DraI), 
x 11 (BanII, Eco24I ,FriOI), 
x 13 (Eam1104I, EarI, Ksp632I), 
x 16 (BssT1I, Eco130I, EcoT14I, ErhI, StyI), 
x 17 (BstSFI, SfcI), and  
x 24 (AcsI, ApoI) 




transferable to another species/strain. The class I ‘RMS’ 
to which S. aureus’ putative alien genes found in the 
lactobacillus belong, is controlled mainly by 3 of 6 gene 
products: the specific restriction endonuclease (hsdR), 
Specificty host DNA stretch (hsdS) and a specific DNA 
methyltransferase (hsdM). All 3 proteins products of 
these genes recognize the same 4 - 8 base pair palindro-
mic nucleotide sequence in the invading viral DNA with 
the former catalysing cleavage of foreign double standard 
DNA and the later functioning to protect the host genomic




Table 3. Table of enzyme activity on HIV-2/SIVssm Genome A.GM.x.MCN13_AY509259 9713 base pairs. 
  
Frequency of cuts No. of enzyme (%) Enzymes cleaving 10 or > times 
1 41 (14.1) 
2 53 (18.2) 
3 29 (1.0) 
4 9 (3.1) 
5 16 (5.5) 
6 10 (3.4) 
7 5 (1.4) 
8 6 (2.1) 
9 7 (1.7) 
10 9 (3.1) 
11 9 (3.1) 
12 5 (1.7) 
16 2 (0.7) 
 
 
x10 (AccB1I, BanI, BshNI, DraII ,Eam1104I, EarI, Eco64I, 
EcoO109I, Ksp632I) x11 (BssT1I, BstSFI, CfrI, EaeI, Eco130I, 
EcoT14I, ErhI,SfcI, StyI) x12 (BstYI, MflI, MspA1I, NspBII, XhoII) 
x16 (AcsI, ApoI) 




Table 4. Table of enzyme activity on Other SIV genome B.FR.83.HXB2_LAI_IIIB_BRU_K03455 (9719 base pairs). 
 
Frequency of cuts No. of enzyme (%) Enzymes cleaving 10 or > times  
1 63 (21.7) 
2 41 (14.1) 
3 11 (3.8) 
4 30 (10.3) 
5 14 (4.8) 
6 8 (2.8) 
7 11 (3.8) 
8 11 (3.8) 
10 3 (1.0) 
11 2 (0.7) 
12 5 (1.7) 
13 2 (0.7) 







x10 (MslI, MspA1I, NspBII), x11 (DraI, Eco57I), x12 (BssT1I, 
Eco130I, EcoT14I, ErhI, StyI), x13 (BstSFI, SfcI), x17 (AcsI, ApoI, 
BstX2I, BstYI, MflI, XhoII) 
 




Table 5. Putative alien genes resulting from horizontal gene transfer (based on homology BLAST analysis) of gram-positive 
bacterial origin. Adapted and Modified from http://www.lacplantcyc.nl. 
 
Orf Organism (best BLAST hit) E-score Identity > Function Remarks 
Gram-positive origin 
lp_0275  Staphylococcus aureus (N315) 1.00E-123 52% manganese 
transporter 
Best hits:S.aureus (E-123), Listeria (E-
103), Nostoc (E-100), Agrobacterium 
(E-92), Rhizobium (E-89) 
lp_0918  Staphylococcus aureus (Mu50) 1.00E-110 29% hypothetical protein Only 1 good hit S.aureus (E-110, 29% 
identity over 1000 aa) 
lp_0938  Staphylococcus aureus (Mu50) 0 42% hsdR, putative type I 
restriction enzyme 
also hits with gram-negatives 
lp_0939  Staphylococcus aureus (N315) 0 60% hsdM protein Best hits with gram positives 
lp_0941 Listeria innocua 1.00E-103 58% integrase Hits with Listeria are by far the best 
lp_1299  Staphylococcus aureus (Mu50) 1.00E-103 41% hypothetical protein 2e hit S.aureus, 3e hit L. lactis (6E-41, 
24% identity) 




DNA from cleavage by the cognate restriction enzyme 
(Murray, 2000; Nelson, 1972; Roberts and Macelis, 1991; 
Janulaitis et al 1992; Kessler and Manta, 1990; Nelson 
and McClelland, 1991; Radasci and Bickle, 1996; Barcus 
and Murray, 1995). In nature, the genes for coding for 
restriction-modification systems are often clustered toget-
her in a region called an "immigration control region”. The 
fact that in the same class of RMS, these genes, or their 
proteins, from differing species/strain origin can recom-
bine to yield restriction enzymes with completely new 
properties, besides the diversity of enzymes shown here 
to cleave the HIV genomes offers avenues for fighting 
resistance. Although vector mediated in vivo use of res-
triction enzymes as a gene based therapy against HIV is 
possible, there are dangers to the human genome that 
contains several of the recognition palindromes (Misaki, 
2005; Web cutter Version 2.0. http://rna.lund-
berg.gu.se/cutter2/; Perelson et al., 1996; Perelson et al., 
1997; Miller et al., 1993; Jolly, 1994; Weissman et al., 
1995). In addition, immunologic rejection is bound to 
occur towards the cell-lines transduced by these viral 
vectors. This leaves only an ex vivo strategy for the 
therapeutic application of these enzymes. 
Lactobacillus bacteria form the predominant commen-
sals of the vagino-cervical mucosa. Recent studies have 
revealed that these bacteria actually form exist in form of 
biofilm lining in the mucosa (Coombs et al., 2003; Barde-
guez et al., 1997; Givan et al., 1997; Patterson et al., 
1998; Hladik et al., 1999; Anderson et al., 1998; Belec et 
al., 1995; Canchaya et al., 2006; Clerici, 1999; McLean 
and Rosenstein, 2000; Klebanoff, 1991). Similarly, seve-
ral recent strategies aimed at modifying lactobacillus to 
express anti-HIV heterogenous proteins as a live micro-
bicide strategy against HIV transmission have emerged 
(Theresa et al., 2003; Liu, et al 2006). Our findings that 
highlight the presence of putative alien restriction genes 
and proteins from S. aureus reveals that the lactobacillus 
metabolic genome pathway genome is innately readily 
amenable to genetic modification and thus artificial engi-
neering to express restriction enzyme genes. Plasmid 
vectors, such as the pOSEL144, can readily be modified 
to carry these genes into lactobacillus (Liu, et al 2006). It 
is believed that modification of native commensal lacto-
bacillus to accord them abilities to express genes coding 
for restriction enzymes that cleave HIV proviral DNA 
offers a novel “live-microbicide” strategy for preventing 
HIV infection in high-risk women. Recombinant strains of 
lactobacillus expressing other antiviral proteins such as 
Cynavarin N and CD4-Ligands have already been dem-
onstrated elsewhere to last over 2 weeks after application 
in the VC mucosa, offering a user friendly convenience 
by eliminating the need for immediate-pre-coital applica-
tion (Liu, et al 2006). The United Nations (UN) Millennium 
Development Goals (MDGs) Genomics working Group of 
the Task Force on Science, Technology, and innovation 
(Task force 10) recently ranked the 10 most vital 





UNMP 2005; and 51). The developing world too, listed its 
own priority applications for these (Greenwood et al., 
2006; Salamanca-Buentello, 2005). In all 8 MDGs, Rege-
nerative Medicine, an emerging interdisciplinary field of 
research and clinical applications focused on the repair, 
replacement, or regeneration of cells, tissues, or organs 
to restore impaired function resulting from any cause, had 
its profound role. Through its approach of nanaotechno-
logy (NT) based medicine (nanomedicine), defined as the 
study, design, application, and exploitation of novel pro-
perties and phenomena of functional materials, devices, 
systems at a nanometer scale (1 - 100 nanometers; 1 
nanometer = 1 x 10-9 of a meter: that is, at atomic and 
molecular levels), regenerative medicine offers many 
solutions to the health problems of the developing world 
(Singer et al., 2005) such as the one discussed in this 
context. Among the top 3 in 10 listed, immune system 
enhancement by engineered immune cells and novel 





Our results indicate that a diversity of bacteria restriction 
enzymes are capable of cleaving the HIV genome, and 
their application in viral infections is feasible, since many 
human orifices where these viruses primary enter are 
colonised by bacteria species. Using this approach may 
provide a novel line of antiviral therapeutic strategies. 
Although HIV is discussed as the primary pathology here, 
this science is transferable to other mucosal acquired 
viral infections such as HPV, HBV, HCV, SARS, and 
influenza. In the next 5 -10 years, I speculate that using 
this approach will form a basis for immunisation, vaccina-
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